Six-year follow-up of the clinical significance of karyotype in acute lymphoblastic leukemia.
暂无分享,去创建一个
C. Bloomfield | J. Rowley | A. de la Chapelle | J. Whang‐Peng | O. Garson | F. Mitelman | Y. Kaneko | A. Sandberg | H. van den Berghe | T. Ruutu | G. Alimena | H. Golomb | A. Goldman | S. Lawler | L. Secker-Walker | P. Philip | E. Prigogina | A. D. L. Chapelle | H. V. D. Berghe
[1] Rivera Gk,et al. Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors , 1987 .
[2] R. Gale,et al. Acute lymphoblastic leukemia in adults: recent progress, future directions. , 1987, Seminars in hematology.
[3] M. Schrappe,et al. Therapy results in five ALL-BFM studies since 1970: implications of risk factors for prognosis. , 1987, Haematology and blood transfusion.
[4] Walker,et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. , 1986, Blood.
[5] A I Goldman,et al. Survivorship analysis when cure is a possibility: a Monte Carlo study. , 1984, Statistics in medicine.
[6] C. Bloomfield,et al. Chromosomal abnormalities and their clinical significance in acute lymphoblastic leukemia. Third International Workshop on Chromosomes in Leukemia. , 1983, Cancer research.
[7] Natalie W. Paul,et al. Birth defects, original article series , 1982 .
[8] J. Whang‐Peng. Clinical significance of chromosomal abnormalities in acute lymphoblastic leukemia , 1981 .
[9] Stephen E. Fienberg,et al. The analysis of cross-classified categorical data , 1980 .
[10] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .